Advertisement

Diabetologia

, Volume 56, Issue 9, pp 1869–1872 | Cite as

Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies?

  • Jens Juul HolstEmail author
Commentary

Keywords

Alpha cells Duct cellular pancreatic cancer Incretins Liraglutide Pancreatitis 

Abbreviations

DPP-4

Dipeptidyl peptidase-4

GLP-1

Glucagon-like peptide-1

In this issue of Diabetologia, Ellenbroek and colleagues present a study of the effects of the glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide, on beta cell function and mass in normoglycaemic mice [1]. The mice were treated with liraglutide at 0.1 mg/kg twice daily (a high but reasonable dose) for either 1 or 6 weeks while they received either a control diet or a high fat diet. Compared with controls, liraglutide improved insulin resistance and attenuated resistance induced by high fat feeding. In the pancreas, a lower beta cell mass was observed in the liraglutide-treated group, which was associated with decreased proliferation of beta cells at 1 week. Despite this, islets isolated from treated mice showed enhanced glucose-stimulated insulin secretion. There was a similar reduction in alpha cell mass such that the alpha to beta cell ratio was preserved. In contrast, acinar cells showed a significantly higher number of proliferating cells following liraglutide treatment in both control and high fat fed mice (as measured using BrdU incorporation), and total pancreatic mass increased somewhat after 6 weeks. Duct cells did not show proliferation. There were no signs of inflammation and levels of pro-inflammatory cytokines were similar in all groups.

These results are interesting in many ways. First, the reported effect on beta cell mass is consistent with the view that beta cell mass in rodents is predominantly regulated by glucose [2]. Thus, the proliferative effects of GLP-1 and GLP-1 agonists are mainly observed in hyperglycaemic animals. Bock et al [3] observed that the effect of liraglutide on beta cell mass (evaluated by stereology, the most reliable technique for morphometric analysis) in normoglycaemic rats was transient, supporting the view that glycaemic regulation overrides the effects of incretins. The lower beta cell mass observed by Ellenbroek et al is consistent with a glucose-lowering effect of GLP-1 even at basal levels [4]. The positive effects on insulin sensitivity and glucose tolerance are in line with those observed in human studies [5], although the mechanism in normoglycaemic animals is unclear. The question is whether or not GLP-1 directly affects peripheral insulin-sensitive tissues (muscle and fat); this has been reported in rodents [6], but is perhaps less likely to occur in humans [7, 8], where improvements in patients with diabetes are generally thought to reflect improved metabolism and weight loss [5]. Weight loss may also play a role in the present study [1], as liraglutide treatment reduced body weight in control and high fat fed mice.

A new finding in this study is that alpha cell mass was reduced similarly to beta cell mass [1]. Initially, this would appear consistent with the inhibitory effect of GLP-1 on alpha cell secretion [9]. However, the mechanism behind the inhibition is far from clear: in contrast to beta cells, it is highly controversial whether or not alpha cells express GLP-1 receptors, with reports ranging from no receptors [10] to 20% of alpha cells expressing them [11]. A cautious guess might be that the expression level is low [12]. It is equally uncertain how GLP-1 lowers glucagon secretion (GLP-1 was even reported to stimulate secretion in isolated alpha cells [13, 14]), but several observations indicate that the inhibition is indirect, resulting from the inhibitory actions of hormones or agents released from neighbouring islet cells (such as somatostatin [15] and beta cell products [14]).

The results obtained by Ellenbroek et al [1] appear at a time when new findings regarding the effects of GLP-1-based therapies have questioned the safety of these therapies. In an online report in Diabetes a team of workers from Los Angeles and Florida reported pancreatic morphological changes in eight diabetes patients treated with GLP-1-based therapies (seven with the dipeptidyl peptidase-4 [DPP-4] inhibitor, sitagliptin, one with exenatide) for less than a year [16]. The pancreatic tissue specimens were obtained freshly post mortem through a collaboration with the Network for Pancreatic Organ Donors with Diabetes (nPOD) funded by the JDRF to promote type 1 diabetes research, and compared with tissue from 12 diabetic patients not receiving GLP-1-based therapies and a group of nondiabetic donors. As one can imagine, the groups were extremely heterogeneous with widely differing circumstances leading to a final hospital stay, e.g. in intensive care units, and to death. The main findings in incretin-treated individuals were a 40% increase in pancreatic mass accompanied by increased proliferation of exocrine cells as well as dysplasia in the form of: intraepithelial neoplasia; hyperplasia of beta and alpha cells (five- to sixfold increases); increased frequency of cells co-staining for insulin and glucagon; peri-/intraductal luminal projections of glucagon immunoreactive cells; and glucagon-producing microadenomas in three donors, one of whom also had a glucagon-producing tumour. There were no signs of pancreatitis in any of the pancreases examined. The study has been heavily criticised, particularly because of the heterogeneity of the groups [17, 18]. Particularly important is a mean 18 year age difference between incretin treated and non-incretin treated patients with diabetes.

However, the studies by Ellenbroek et al [1] and Butler et al [16] have in common an increase in the mass of the (exocrine) pancreas. Do GLP-1 and GLP-1 receptor agonists cause pancreatic growth? And if they do, what does that mean for treatment safety?

Pancreatic growth is generally not reported in the studies available to date. It is also unclear whether or not GLP-1 receptors are expressed in the acinar tissue. However, it should be noted that exenatide was originally isolated using a bioassay based on cAMP accumulation in guinea pig pancreatic acini [19], indicating that exenatide must somehow interact with this tissue (although it may be possible that the acinus preparations could have been contaminated with islet cells). It has also been reported that exenatide enhances cholecystokinin-induced pancreatic enzyme secretion (but has little effect alone) [20], perhaps consistent with reports of slightly raised lipase levels during GLP-1 agonist therapy [21]. In preclinical studies provided by the pharmaceutical companies for registration of GLP-1-based therapeutics, increases in pancreatic mass have not been reported [22], and in one study of exenatide, pancreas mass was actually reduced [23]. In extensive studies on the pancreatic effects of liraglutide, Nyborg et al examined pancreases from 1,438 animals, of which more than 1,000 were treated for 2 years (lifetime) at up to 60-fold higher doses than the equivalent human therapeutic doses [22]; increases in pancreas size were not noted, and in monkeys followed for 87 weeks of therapy there was no growth of the pancreas. However, a study by Koehler et al of exenatide and liraglutide in mice [24] found increases in pancreatic size (not associated with inflammation), and in female (but not in male) monkeys given liraglutide for 52 weeks there was apparently an increase in pancreas mass (mentioned in a news report in the British Medical Journal [25]), contrasting with the lack of effect in the 87 week study in monkeys [22]. Thus, it is difficult to conclude anything from the preclinical studies. In the cases where an increase was observed, this was not associated with inflammation (i.e. pancreatitis). The human pancreas donor study by Butler et al [16] included only one patient treated with a GLP-1 agonist (exenatide), whereas the others were treated with the DPP-4 inhibitor sitagliptin, for which there are no preclinical data (derived from extensive studies [26]) suggesting growth of the pancreas or any other pathology. It should also be considered that GLP-1 plasma levels during DPP-4 inhibitor treatment are only slightly elevated and still fall within the normal range [27]. Rather, it should be noted that the diabetic control group in the donor study [16] probably included several (or a majority of) pancreases from patients with type 1 diabetes, which are known to be smaller than those of controls [28]. A similar reservation applies to the observed beta cell hyperplasia: some years ago a trophic effect on beta cells would have been received with enthusiasm, because it would support notions of protective or restitutive effects of the GLP-1 therapies on beta cells, but despite the potential to enhance beta cell mass in young rodents [29], no studies so far have revealed beta cell tumours (insulinomas) resulting from GLP-1 therapies, consistent with the concept that GLP-1 therapy does not enhance beta cell mass in humans [30].

The reduction in alpha cell mass in the mouse study by Ellenbroek et al [1] also contrasts with Butler’s finding of alpha cell hyperplasia [16]. However, in humans, similar, clearly age-dependent changes have been observed in autopsy studies [31, 32] suggesting that the Butler observations are mainly due to the age difference between the groups. The hyperplasia in the Butler study led some to think of the alpha cell hyperplasia that has been observed in mice with glucagon receptor mutations and animals treated with glucagon antagonists [33, 34], based on the idea that, if GLP-1 therapies inhibit glucagon secretion, they may also cause alpha cell hyperplasia. However, the hyperplasia found in glucagon receptor knockout mice is due to a hepatic factor and is not observed after selective knockout of glucagon receptors in the pancreas [35]. More importantly, any hyperplasia is invariably and immediately associated with hyperglucagonaemia [36], which has never been observed as a consequence of GLP-1-based therapies, which lower glucagon levels.

Duct changes similar to those observed by Butler et al [16] have not generally been observed in preclinical studies except in transgenic mice with mutated Kras genes leading to inflammation [37], and therefore would be suspected to result more from the mutations than from therapy. Again, the 18 year age difference between the GLP-1 treated patients and the controls in Butler’s study should be kept in mind, since it is well established that pancreatic pathologies (including pancreatic intraepithelial neoplasias [PanINs]) increase considerably with age.

In conclusion, the study by Ellenbroek et al [1] does raise the question of whether GLP-1 agonism under certain circumstances may have a (possibly transient) trophic effect on the pancreatic acinar tissue in mice (but apparently not in rats), but importantly this seems never to be related to inflammation, and cannot be interpreted to support the observations by Butler et al [16]. The results regarding endocrine changes also provide no mechanistic support for a causal relationship between GLP-1-based therapies and the other observations made by Butler et al. A conference held by the NIH on June 12–13 2013 (www2.niddk.nih.gov/News/Calendar/PDPC2013) discussed many of the issues mentioned above and expressed very similar views.

Notes

Duality of interest

JJH has been consulting with NovoNordisk, Sanofi, GSK, Bristol-Myers Squibb, MSD and Zealand and is currently receiving research support from MSD.

Contribution statement

The author is the sole contributor to this article.

References

  1. 1.
    Ellenbroek JH, Töns HAM, Westerouen van Meeten MJA et al (2013) Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice. Diabetologia. doi: 10.1007/s00125-013-2957-2 PubMedGoogle Scholar
  2. 2.
    Sturis J, Gotfredsen CF, Romer J et al (2003) GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 140:123–132PubMedCrossRefGoogle Scholar
  3. 3.
    Bock T, Pakkenberg B, Buschard K (2003) The endocrine pancreas in non-diabetic rats after short-term and long-term treatment with the long-acting GLP-1 derivative NN2211. APMIS 111:1117–1124PubMedCrossRefGoogle Scholar
  4. 4.
    Hvidberg A, Nielsen MT, Hilsted J, Orskov C, Holst JJ (1994) Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. Metabolism 43:104–108PubMedCrossRefGoogle Scholar
  5. 5.
    Zander M, Madsbad S, Madsen JL, Holst JJ (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824–830PubMedCrossRefGoogle Scholar
  6. 6.
    Valverde I, Villanueva Penacarrillo ML (1996) In vitro insulinomimetric effects of GLP-1 in liver, muscle and fat. Acta Physiol Scand 157:359–360PubMedCrossRefGoogle Scholar
  7. 7.
    Toft-Nielsen M, Madsbad S, Holst JJ (1996) The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 45:552–556CrossRefGoogle Scholar
  8. 8.
    Orskov L, Holst JJ, Moller J et al (1996) GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 39:1227–1232PubMedCrossRefGoogle Scholar
  9. 9.
    Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87:1409–1439PubMedCrossRefGoogle Scholar
  10. 10.
    Moens K, Heimberg H, Flamez D et al (1996) Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes 45:257–261PubMedCrossRefGoogle Scholar
  11. 11.
    Heller RS, Kieffer TJ, Habener JF (1997) Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas. Diabetes 46:785–791PubMedCrossRefGoogle Scholar
  12. 12.
    De Marinis YZ, Salehi A, Ward CE et al (2010) GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis. Cell Metab 11:543–553PubMedCrossRefGoogle Scholar
  13. 13.
    Ding WG, Renstrom E, Rorsman P, Buschard K, Gromada J (1997) Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism. Diabetes 46:792–800PubMedCrossRefGoogle Scholar
  14. 14.
    Ishihara H, Maechler P, Gjinovci A, Herrera PL, Wollheim CB (2003) Islet beta-cell secretion determines glucagon release from neighbouring alpha-cells. Nat Cell Biol 5:330–335PubMedCrossRefGoogle Scholar
  15. 15.
    de Heer J, Rasmussen C, Coy DH, Holst JJ (2008) Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 51:2263–2270PubMedCrossRefGoogle Scholar
  16. 16.
    Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC (2013) Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. doi: 10.2337/db12-1686 Google Scholar
  17. 17.
    Nauck MA (2013) A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks. Diabetes Care. doi: 10.2337/dc12-2504 Google Scholar
  18. 18.
    Kahn SE (2013) Incretin therapy and islet pathology: a Time for Caution. Diabetes 62:2178–2180Google Scholar
  19. 19.
    Eng J, Kleinman WA, Singh L, Singh G, Raufman JP (1992) Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267:7402–7405PubMedGoogle Scholar
  20. 20.
    Malhotra R, Singh L, Eng J, Raufman JP (1992) Exendin-4, a new peptide from Heloderma suspectum venom, potentiates cholecystokinin-induced amylase release from rat pancreatic acini. Regul Pept 41:149–156PubMedCrossRefGoogle Scholar
  21. 21.
    Lando HM, Alattar M, Dua AP (2013) Elevated amylase and lipase levels in patients using glucagon-like peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting. Endocr Pract 18:472–477CrossRefGoogle Scholar
  22. 22.
    Nyborg NC, Molck AM, Madsen LW, Knudsen LB (2012) The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes 61:1243–1249PubMedCrossRefGoogle Scholar
  23. 23.
    Tatarkiewicz K, Belanger P, Gu G, Parkes D, Roy D (2013) No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks. Diabetes Obes Metab 15:417–426PubMedCrossRefGoogle Scholar
  24. 24.
    Koehler JA, Baggio LL, Lamont BJ, Ali S, Drucker DJ (2009) Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 58:2148–2161PubMedCrossRefGoogle Scholar
  25. 25.
    Cohen D (2013) Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed? Br Med J 346:1–9CrossRefGoogle Scholar
  26. 26.
    Engel SS, Williams-Herman DE, Golm GT et al (2010) Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 64:984–990PubMedCrossRefGoogle Scholar
  27. 27.
    Mari A, Sallas WM, He YL et al (2005) Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 90:4888–4894PubMedCrossRefGoogle Scholar
  28. 28.
    Williams AJ, Thrower SL, Sequeiros IM et al (2012) Pancreatic volume is reduced in adult patients with recently diagnosed type 1 diabetes. J Clin Endocrinol Metab 97:E2109–E2113PubMedCrossRefGoogle Scholar
  29. 29.
    Xu G, Stoffers DA, Habener JF, Bonner-Weir S (1999) Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270–2276PubMedCrossRefGoogle Scholar
  30. 30.
    Bunck MC, Corner A, Eliasson B et al (2011) Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 34:2041–2047PubMedCrossRefGoogle Scholar
  31. 31.
    Grimelius L, Hultquist GT, Stenkvist B (1975) Cytological differentiation of asymptomatic pancreatic islet cell tumours in autopsy material. Virchows Arch A Pathol Anat Histol 365:275–288PubMedCrossRefGoogle Scholar
  32. 32.
    Kimura W, Kuroda A, Morioka Y (1991) Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Dig Dis Sci 36:933–942PubMedCrossRefGoogle Scholar
  33. 33.
    Bagger JI, Knop FK, Holst JJ, Vilsboll T (2011) Glucagon receptor antagonism for the treatment of type 2 diabetes. Diabetes Obes Metab 13:965–971PubMedCrossRefGoogle Scholar
  34. 34.
    Gelling RW, Du XQ, Dichmann DS et al (2003) Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A 100:1438–1443PubMedCrossRefGoogle Scholar
  35. 35.
    Longuet C, Robledo AM, Dean ED et al (2013) Liver-specific disruption of the murine glucagon receptor produces alpha-cell hyperplasia: evidence for a circulating alpha-cell growth factor. Diabetes 62:1196–1205PubMedCrossRefGoogle Scholar
  36. 36.
    Brand CL, Jorgensen PN, Knigge U et al (1995) Role of glucagon in maintenance of euglycemia in fed and fasted rats. Am J Physiol 269:E469–E477PubMedGoogle Scholar
  37. 37.
    Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC (2012) Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Krasn(G12D) mouse model. Diabetes 61:1250–1262PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.NNF Center for Basic Metabolic Research, Department of Biomedical Sciences, Panum InstituteUniversity of CopenhagenCopenhagenDenmark

Personalised recommendations